Current Report Filing (8-k)
January 04 2019 - 4:13PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of
1934
Date of Report (Date of earliest event reported): December 31,
2018
CELLULAR BIOMEDICINE GROUP, INC.
(Exact
name of registrant as specified in its charter)
Delaware
|
|
001-36498
|
|
86-1032927
|
(State
or other Jurisdiction of Incorporation)
|
|
(Commission
File Number)
|
|
(IRS
Employer Identification No.)
|
19925 Stevens Creek Blvd., Suite 100
Cupertino, California
|
95014
|
(Address
of Principal Executive Offices)
|
(Zip
Code)
|
Registrant’s
telephone number, including area code:
(
347) 905
5663
(
408)
973-7884
(Former
name or former address, if changed since last report.)
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
☐
|
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
|
☐
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
☐
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b))
|
☐
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c))
|
Emerging
growth company ☐
If an
emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act.
☐
Item 8.01 Other Events
As
previously reported on a Current Report on Form 8-K filed with the
Securities and Exchange Commission, Cellular Biomedicine Group,
Inc. (the “Company”) commenced a share repurchase
program (the “2018 Share Repurchase Program”) on
October 10, 2018, pursuant to which the Company may, from time to
time, purchase shares of its common stock for an aggregate purchase
price not to exceed approximately $8.48 million. Share repurchases
may be executed in open market transactions pursuant to a plan
adopted in accordance with Rule 10b5-1 of the Securities Exchange
Act of 1934, as amended (the “Exchange Act”) and in
accordance with Rule 10b-18 of the Exchange Act. The
authorization for the 2018 Share Repurchase Program may be
terminated by the Company in its discretion at any
time.
On
December 31, 2018, the Company extended the implementation period
of the 2018 Repurchase Program for another three months, or until
March 31, 2019. The other terms and conditions of the program
remain unchanged.
SIGNATURE
Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant
has caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
Cellular Biomedicine Group, Inc.
|
|
|
|
|
|
Date:
January 4, 2019
|
By:
|
/s/ Bizuo
(Tony) Liu
|
|
|
|
Bizuo
(Tony) Liu
|
|
|
|
Chief
Executive Officer
|
|
|
|
|
|
Cellular Biomedicine (NASDAQ:CBMG)
Historical Stock Chart
From Aug 2024 to Sep 2024
Cellular Biomedicine (NASDAQ:CBMG)
Historical Stock Chart
From Sep 2023 to Sep 2024